924708-48-5

Upstream product

• 1761-62-2 5-iodosalicyclaldehyde 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 38170-02-4 4-iodosalicylaldehyde 
• 90-02-8 salicylaldehyde 

Downstream Products

• 943341-61-5 (2-vinyl-4-iodophenyl)-4-methoxymethoxybenzoate 
• 924708-52-1 toluene-4-sulfonic acid 2-{2-[4-(tert-butyl-dimethyl-silanyloxy)-phenoxy]-5-iodo-phenyl}-2-hydroxy-ethyl ester 
• 924708-50-9 (R)-1-(2-(4-(tert-butyldimethylsilyloxy)phenoxy)-5-iodophenyl)ethane-1,2-diol 
• 924708-54-3 (R)-2-(2-(4-(tert-butyldimethylsilyloxy)phenoxy)-5-iodophenyl)propan-1-ol 
• 924708-53-2 (S)-2-(2-(4-(tert-butyldimethylsilyloxy)phenoxy)-5-iodophenyl)propan-1-ol 
• 924708-51-0 (R)-tert-butyl(4-(4-iodo-2-(oxiran-2-yl)phenoxy)phenoxy)dimethylsilane 
• 925230-87-1 4-[2-(2-hydroxy-1-methyl-ethyl)-4-propenyl-phenoxy]-phenol 
• 132114-11-5 ratanhine 
• 943341-57-9 C₄₀H₃₈O₈ 
• 943341-63-7 (2-(1-bromoethenyl)-4-iodophenyl)-4-methoxymethoxybenzoate 
• 943341-62-6 (2-(1,2-dibromoethyl)-4-iodophenyl)-4-methoxymethoxybenzoate 
• 924708-49-6 tert-butyl(4-(4-iodo-2-vinylphenoxy)phenoxy)dimethylsilane 

Relevant academic research and scientific papers

Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors

A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. The 8-substituted homosulfocoumarins were the most effective hCA IX/XII inhibitors followed by the 7-substituted derivatives, whereas the substitution pattern in position 9 led to less effective binders for the transmembrane, tumour-associated isoforms IX/XII. The cytosolic isoforms hCA I and II were not inhibited by these compounds, similar to the sulfocoumarins/coumarins investigated earlier. As hCA IX and XII are validated anti-tumour targets, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance.

SYSTEM FOR CONTROLLING THE REACTIVITY OF BORONIC ACIDS

A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.

Concise synthesis of rodgersinol and determination of the C-10 absolute configuration

Rodgersinol was synthesized via seven linear steps in 31% overall yield, and the absolute configuration of the C-10 stereogenic center was elucidated. The key feature of the synthesis involves the efficient Cu(II)-mediated coupling of two aromatic moietie

A simple and modular strategy for small molecule synthesis: Iterative Suzuki-Miyaura coupling of B-protected haloboronic acid building blocks

We herein describe a simple and highly modular strategy for small molecule synthesis involving the iterative cross-coupling of B-protected bifunctional haloboronic acids. Enabling this approach, we have newly discovered that the pyramidalization of boroni